Chest
Selected ReportsRefractory Sarcoidosis Responding to Infliximab*
Section snippets
Case Report
A 50-year-old white woman was referred to our institution in 1997 for management of refractory pulmonary sarcoidosis and uveitis. The diagnosis had been confirmed 8 months prior by transbronchial biopsy. She had been receiving maintenance therapy since that time with 60 mg prednisone daily. At the time of her initial visit in 1997, she had experienced a 60-lb weight gain, worsening hypertension, and glucose intolerance as complications of systemic steroid therapy. Her initial examination
Discussion
We have described a patient with multisystem sarcoidosis, including pulmonary, cutaneous, ocular, and cardiac involvement, that progressed despite aggressive therapy. Her clinical course included multiple exacerbations of the disease and numerous therapeutic side effects. Only after the institution of infliximab therapy, as part of a multidrug regimen, did the oculocutaneous sarcoid resolve. This case illustrates the impact that targeted anticytokine therapy may have on selected patients with
References (18)
- et al.
Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy
J Am Acad Dermatol
(2003) - et al.
Myocardial sarcoidosis
Chest
(1993) - et al.
The gene polymorphism of tumor necrosis factor-beta, but not that of tumor necrosis factor-alpha, is associated with the prognosis of sarcoidosis
Chest
(2001) - et al.
Thalidomide for chronic sarcoidosis
Chest
(2002) - et al.
Infliximab for refractory sarcoidosis
Sarcoidosis Vasc Diffuse Lung Dis
(2001) - et al.
Refractory neurosarcoidosis responding to infliximab
Neurology
(2002) - et al.
Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy
Ann Intern Med
(2001) - et al.
Pulmonary sarcoidosis: patterns of cytokine releasein vitro
Eur Respir J
(1996) - et al.
TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection
J Immunol
(2002)
Cited by (113)
Sarcoidosis
2019, Journal Francais d'OphtalmologieSarcoidosis
2018, Journal Francais d'OphtalmologieSerial FDG-PET scans help to identify steroid resistance in cardiac sarcoidosis
2017, International Journal of CardiologyIdiopathic granulomatous interstitial nephritis responsive to mycophenolate mofetil therapy
2014, American Journal of Kidney DiseasesCitation Excerpt :Our patient responded well to corticosteroid therapy, but then experienced steroid-induced diabetes mellitus, which led to the use of MMF as a corticosteroid-sparing agent. There have been several promising reports of the use of corticosteroid-sparing agents, such as azathioprine, methotrexate, and infliximab, in patients with systemic sarcoidosis with and without renal involvement.13-18 The potential benefit of MMF in the treatment of systemic sarcoidosis also has been reported.14,19-21
Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy
2013, Seminars in Arthritis and Rheumatism